Systematic Financial Management LP Acquires 214,272 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Systematic Financial Management LP raised its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 53.9% in the third quarter, Holdings Channel reports. The firm owned 611,746 shares of the life sciences company’s stock after purchasing an additional 214,272 shares during the period. Systematic Financial Management LP’s holdings in Integra LifeSciences were worth $11,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Sachem Head Capital Management LP bought a new position in Integra LifeSciences in the 3rd quarter valued at $44,153,000. Centiva Capital LP bought a new position in shares of Integra LifeSciences during the 3rd quarter worth $192,000. Clearline Capital LP grew its stake in shares of Integra LifeSciences by 226.8% during the 3rd quarter. Clearline Capital LP now owns 230,397 shares of the life sciences company’s stock worth $4,186,000 after acquiring an additional 159,903 shares during the period. Walleye Capital LLC grew its stake in shares of Integra LifeSciences by 758.7% during the 3rd quarter. Walleye Capital LLC now owns 234,506 shares of the life sciences company’s stock worth $4,261,000 after acquiring an additional 207,196 shares during the period. Finally, FORA Capital LLC bought a new position in shares of Integra LifeSciences during the 3rd quarter worth $436,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Truist Financial cut their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Finally, Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday. They issued an “underweight” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $23.00.

Insider Transactions at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $23.86 on Friday. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -265.11, a P/E/G ratio of 0.84 and a beta of 1.15. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The stock’s 50-day moving average is $21.19 and its 200 day moving average is $23.92.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 EPS. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.